RxDoctor Payments Data

Richard Hamill

Infectious Disease · Houston, TXNPI 1942224795

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $136,500 of the $136,520 with a category attached, or 100.0%. Modernatx, Inc. accounts for 100.0% of it on its own, with 1 other manufacturer making up the rest. Among infectious disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$136,520in general payments, 2019–2025

Across 7 payments — averaging $19,503 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$137K
  • Merck$20
$860,989in research payments, 2019–2025

Across 50 payments — averaging $17,220 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$746K
  • Pfizer$115K

What the payments were for

  • Consulting fees$136,500100%
  • Education$200%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.6$136,500
Merck1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$136,520 in reported general payments places this provider in the 95th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas

Other infectious disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →